Mark Johan Arends

Prof. Dr. Mark Johan Arends

Cancer Research UK Edinburgh Centre, Edinburgh, City of Edinburgh, UK
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2016 in Virchows Archiv
Verified
Journal Article
Open access
PDF file
MMMike F. Müller
Mike F. Müller
AIAshraf E. K. Ibrahim
Ashraf E. K. Ibrahim
MAMark Johan Arends
Mark Johan Arends
Colorectal cancer (CRC) shows variable underlying molecular changes with two major mechanisms of genetic instability: chromosomal instability and microsatellite instability. This review aims to delineate the different pathways of colorectal carcinogenesis and provide an overview of the most recent advances in molecular pathological classification systems for colorectal cancer. Two molecular pathological classification systems for CRC have recently been proposed. Integrated molecular analysis by The Cancer Genome Atlas project is based on a wide-ranging genomic and transcriptomic characterisation study of CRC using array-based and sequencing technologies. This approach classified CRC into two major groups consistent with previous classification systems: (1) ∼16 % hypermutated cancers with either microsatellite instability (MSI) due to defective mismatch repair (∼13 %) or ultramutated cancers with DNA polymerase epsilon proofreading mutations (∼3 %); and (2) ∼84 % non-hypermutated, microsatellite stable (MSS) cancers with a high frequency of DNA somatic copy number alterations, which showed common mutations in APC, TP53, KRAS, SMAD4, and PIK3CA. The recent Consensus Molecular Subtypes (CMS) Consortium analysing CRC expression profiling data from multiple studies described four CMS groups: almost all hypermutated MSI cancers fell into the first category CMS1 (MSI-immune, 14 %) with the remaining MSS cancers subcategorised into three groups of CMS2 (canonical, 37 %), CMS3 (metabolic, 13 %) and CMS4 (mesenchymal, 23 %), with a residual unclassified group (mixed features, 13 %). Although further research is required to validate these two systems, they may be useful for clinical trial designs and future post-surgical adjuvant treatment decisions, particularly for tumours with aggressive features or predicted responsiveness to immune checkpoint blockade.

1 April 2020 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
NSNicole M. Sodir
Nicole M. Sodir
RKRoderik M. Kortlever
Roderik M. Kortlever
VBValentin Barthet
Valentin Barthet
TCTania Campos
Tania Campos
LPLuca Pellegrinet
Luca Pellegrinet
GEGerard I. Evan
Gerard I. Evan
The signature features of pancreatic ductal adenocarcinoma (PDAC) are its fibroinflammatory stroma, poor immune activity, and dismal prognosis. We show that acute activation of Myc in indolent pancreatic intraepithelial neoplasm (PanIN) epithelial cells in vivo is, alone, sufficient to trigger immediate release of instructive signals that together coordinate changes in multiple stromal and immune-cell types and drive transition to pancreatic adenocarcinomas that share all the characteristic stromal features of their spontaneous human counterpart. We also demonstrate that this Myc-driven PDAC switch is completely and immediately reversible: Myc deactivation/inhibition triggers meticulous disassembly of advanced PDAC tumor and stroma and concomitant death of tumor cells. Hence, both the formation and deconstruction of the complex PDAC phenotype are continuously dependent on a single, reversible Myc switch. Significance: We show that Myc activation in indolent KrasG12D-induced PanIN epithelium acts as an immediate pleiotropic switch, triggering tissue-specific signals that instruct all the diverse signature stromal features of spontaneous human PDAC. Subsequent Myc deactivation or inhibition immediately triggers a program that coordinately disassembles PDAC back to PanIN. See related commentary by English and Sears, p. 495.

6 March 2020 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
GCGuia Cerretelli
Guia Cerretelli
AAAnn Ager
Ann Ager
MAMark Johan Arends
Mark Johan Arends
IFIan M Frayling
Ian M Frayling

24 November 2021 in Nature
Verified
Journal Article
Closed access
PDF file
LMLee Mulderrig
Lee Mulderrig
JGJuan I. Garaycoechea
Juan I. Garaycoechea
ZTZewen Tuong
Zewen Tuong
CMChristopher L. Millington
Christopher L. Millington
FDFelix A. Dingler
Felix A. Dingler
KPKetan J. Patel
Ketan J. Patel

12 February 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
SCSiobhan Crittenden
Siobhan Crittenden
MGMarie Goepp
Marie Goepp
JPJolinda Pollock
Jolinda Pollock
CRCalum T Robb
Calum T Robb
DSDanielle J Smyth
Danielle J Smyth
CYChengcan Yao
Chengcan Yao
PGE 2 inhibits T regs and promotes intestinal inflammation through actions on mononuclear phagocytes and the gut microbiota.

6 February 2024 in Virchows Archiv
Verified
Journal Article
Open access
PDF file
PDPhilip D. Dunne
Philip D. Dunne
MAMark Johan Arends
Mark Johan Arends
Colorectal cancer (CRC) has a broad range of molecular alterations with two major mechanisms of genomic instability (chromosomal instability and microsatellite instability) and has been subclassified into 4 consensus molecular subtypes (CMS) based on bulk RNA sequence data. Here, we update the molecular pathological classification of CRC with an overview of more recent bulk and single-cell RNA data analysis for development of transcriptional classifiers and risk stratification methods, taking into account the marked inter-tumoural and intra-tumoural heterogeneity of CRC. The importance of the stromal and immune components or tumour microenvironment (TME) to prognosis has emerged from these analyses. Attempts to remove the contribution of the tumour microenvironment and reveal neoplastic-specific transcriptional traits involved identification of the CRC intrinsic subtypes (CRIS). The use of immunohistochemistry and digital pathology to implement classification systems are evolving fields. Conventional adenoma versus serrated polyp pathway transcriptomic analysis and characterisation of canonical LGR5+ crypt base columnar stem cell versus ANXA1+ regenerative stem cell phenotypes emerged as key properties for improved understanding of transcriptional signals involved in molecular subclassification of colorectal cancers. Recently, classification by three pathway-derived subtypes (PDS1-3) has been developed, revealing a continuum of intrinsic biology associated with biological, stem cell, histopathological, and clinical attributes.